STAT

Opinion: Cure ‘futures’ offer a way to pay for million-dollar medicines

Effective new drugs can make the world a better place — unless they aren’t accessible because those making the breakthroughs charge an enormous price to get a decent profit because they can, or because their investors demand it.

People who create viable businesses and their investors have a right to earn a return on the resources they expend to solve a problem, including finding cures for previously incurable diseases. But that is turning out to be problematic when it comes to new medicines, especially those with million-dollar price tags.

A recent focused on a newly approved leukemia treatment with a high success rate. The total treatment cost

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks